Evidence map›Paper›PMID 40406491›Full record

ArticleFrontiers in pharmacology2025

Investigation of

Jiarui Zheng, Weiming Wang, Wenting Song, Yehao Zhang, Mingjiang Yao, Guangrui Wang, Zishan Huang, Feng Li, Junguo Ren, Li Lin and 2 more

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jiarui ZhengInstitute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing Key Laboratory of Pharmacology of Traditional Chinese Medicine, Beijing, China.
Weiming WangInstitute of Chinese Medicine, Heilongjiang Academy of Traditional Chinese Medicine, Harbin, China.
Wenting SongInstitute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing Key Laboratory of Pharmacology of Traditional Chinese Medicine, Beijing, China.
Yehao ZhangInstitute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing Key Laboratory of Pharmacology of Traditional Chinese Medicine, Beijing, China.
Mingjiang YaoInstitute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing Key Laboratory of Pharmacology of Traditional Chinese Medicine, Beijing, China.
Guangrui WangInstitute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing Key Laboratory of Pharmacology of Traditional Chinese Medicine, Beijing, China.
Zishan HuangInstitute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing Key Laboratory of Pharmacology of Traditional Chinese Medicine, Beijing, China.
Feng LiInstitute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing Key Laboratory of Pharmacology of Traditional Chinese Medicine, Beijing, China.
Junguo RenInstitute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing Key Laboratory of Pharmacology of Traditional Chinese Medicine, Beijing, China.
Li LinInstitute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing Key Laboratory of Pharmacology of Traditional Chinese Medicine, Beijing, China.
Xiaodi FanInstitute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing Key Laboratory of Pharmacology of Traditional Chinese Medicine, Beijing, China.
Jianxun LiuInstitute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing Key Laboratory of Pharmacology of Traditional Chinese Medicine, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study systematically elucidates the therapeutic mechanism of Methods: Potential drug targets of FS and AV-related disease targets were systematically retrieved from TCMSP, SWISS Target Prediction, GeneCards, and DisGeNET databases. The putative therapeutic targets of FS against AV were identified through target overlap analysis between drug and disease targets. Functional enrichment analyses of GO terms, KEGG pathways, and disease associations were performed using DAVID database, with results visualized by Cytoscape software. Molecular docking validation and binding affinity visualization between FS components and target proteins were carried out using PubChem database and PyMOL software. The AV animal model was established by bilateral ovariectomy (OVX). To validate FS's effects on target protein expression, immunohistochemical staining and Western blot analyses were performed. Results: Through target intersection analysis between 137 drug targets and 1,777 disease targets, a total of 100 potential therapeutic targets were identified for FS in AV treatment. Subsequent core gene screening revealed key targets, namely, EGFR, AKT1, ESR1, and TNF. GO and KEGG enrichment analyses demonstrated significantly enriched pathways, with the PI3K/AKT signaling pathway showing particular relevance. Molecular docking analysis revealed strong binding affinity between FS components and the functional domains of EGFR, AKT1, and ESR1. An OVX-induced rat AV model was successfully established, with pathological and molecular validation achieved via immunohistochemistry and Western blot analyses. FS treatment significantly normalized the dysregulated expression levels of p-PI3K/PI3K, p-AKT/AKT, ERα, EGF, and EGFR. Conclusion: FS demonstrates multi-target regulatory capacity, specifically modulating p-PI3K/PI3K, p-AKT/AKT, ERα, EGF, and EGFR signaling pathways, which substantiates its potential as a promising therapeutic agent for AV. These findings provide mechanistic insights into FS's therapeutic targets against AV, establishing a theoretical foundation for its translational application in AV therapy.

Indexed as

atrophic vaginitisexperimental verificationFructus sophorae extractmolecular dockingnetwork pharmacology

Identifiers

PMID40406491
PMCPMC12095276

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.